---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023006"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:44:28.400526+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biofrontera appoints George Jones as Chief Commercial Officer effective August 25, 2025

## Summary
- George Jones named CCO of Biofrontera (Nasdaq: BFRI), bringing over 25 years of commercial leadership in pharmaceuticals and biotech.
- Compensation: $315,000 base salary, up to 50% bonus, and at least 100,000 stock options with one-year vesting per year over three years.
- Jones previously served as COO at UpScriptHealth, where partnership revenues increased more than threefold, and held VP roles at Currax Pharmaceuticals and Pernix Therapeutics.
- Appointment follows Biofrontera's agreement to acquire US rights to Ameluz and RhodoLED from Biofrontera AG, reducing royalty from 25%-35% to 12%-15% of net sales.
- Company states the management strengthening and improved royalty terms will bring it significantly closer to cash break-even.

## SEC filing metadata
- accession: 0001641172-25-023006
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000164117225023006/0001641172-25-023006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000164117225023006/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023006
- JSON: https://secwatch.observer/filing/0001641172-25-023006.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.